Sudarshan Pharma Migrates to NSE Main Board Effective 27th Oct'26
Sudarshan Pharma Industries Ltd 路 Others (Uncategorized) 路 23 Oct 2026, 11:55 pm
Sudarshan Pharma Migrates to NSE Main Board Effective 27th Oct'26 Sudarshan Pharma Industries has received approval from the National Stock Exchange of India (NSE) to list its equity shares on the Main Board (Capital Market Segment), effective 27th Oct'26, migrating from the BSE SME platform. A total of 254,470,600 fully paid-up equity shares of Re. 1/- each will trade under the symbol SUDARSHAN in the EQ series with a market lot of one share. Of the total equity capital, 117,244,110 shares are free from lock-in, while the remaining shares are locked in until Dec'27 and Feb'28.
Original exchange filing (PDF)
More announcements from Sudarshan Pharma Industries Ltd
- Pursuant to Regulation 30 and other applicable Regulations, if any, of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (''SEBI Listing Regulations''), we inform .... 路 09 Nov 2026
- In terms of Regulation 30 read with Para A of Part A of Schedule III to the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we hereby submit the updated Investor .... 路 07 Nov 2026
- In continuation of the Company''s letter dated 30/Oct/2026 (ref. no. SPIL/CS/2026-2027/72), the Board of Directors at its Meeting held on 29/Oct/2026 have approved the proposal to raising .... 路 31 Oct 2026
- This is to inform you that the Board of Directors of the Company at its Board Meeting held on 29/Oct/2026 has approved the proposal to raising funds through issue and allotment of up to .... 路 30 Oct 2026
- We are submitting herewith the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/Sep/2026 路 30 Oct 2026
- We are submitting the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/Sep/2026 路 30 Oct 2026
- Sudarshan Pharma Industries Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Fund raising. 路 29 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 and Fund Raising 路 29 Oct 2026
